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after Transplantation
Introduction
The paper by Ho et al. (1) in this issue of
Pediatric Transplantation launches a symposium
on donor-specific antibodies after transplanta-
tion. During the 50-or-so-year history of clinical
transplantation, no subject has commanded
greater attention and provoked greater contro-
versy. The attention to donor-specific antibodies
derives in part from the use of these unique
reagents to define the major histocompatibility
locus (2) and use in tissue typing (3) and in part
from use of sera of a potential recipient for cross-
matching to prevent immediate rejection (4).
Today, donor-specific antibodies might offer
insight into the immunological responsiveness
of a recipient against their graft and hence a
warning about the risk of rejection.
Donor-specific antibodies also spark contro-
versy. Some believe these antibodies cause the
most important types of rejection, while others
believe they merely mark the immune or inflam-
matory condition. Some have found these anti-
bodies can modify grafts or the immune response
to grafts that actually protects against rejection.
Controversy about whether donor-specific anti-
bodies are effectors or just markers of immunity
to a graft is of more than academic import, as
one now can apply specific but also expensive
and potentially toxic therapies to suppress or
deplete these antibodies.
Whether and to what extent donor-specific
antibodies elicited by transplantation determine
the fate of grafts remains to be settled. The
complexity of this question and the difficulties
faced by those who have tried to answer it were
critically and thoroughly summarized by Stetson
in 1963 (5). Part of the complexity stems from the
fact that antibodies can protect as well as injure
grafts (6) and in part from the fact that organ
grafts are far more susceptible to antibody-
mediated injury than cell and tissue grafts (7).
Opposing the preeminence of antibody as an
effector of graft outcome were the seminal studies
of Mitchison (8) showing that alloreactivity is
transferred by cells but not by serum and Brent
et al. (9) likening the allogeneic response to the
delayed-type hypersensitivity reaction. The
advent and successful use in transplantation of
pharmaceutical agents relatively selective for T
cells appeared to resolve the argument, at least
for the first 30 yr of clinical transplantation, in
favor of cells.
However, today, it would seem more attention
is devoted to humoral than to cellular immunity
to transplantation. Successful control of acute
cellular immunity led to the recognition that the
long-term success of organ allografts is threat-
ened mainly by antibody-mediated chronic vas-
cular and interstitial diseases that demonstrably
resist the pharmaceutical agents so effective at
suppressing cellular immunity. Moreover, today,
in subjects treated with immunosuppressive
agents, the outcome of transplantation correlates
more closely with humoral than with cellular
immune responses (10). And, improvements in
overall survival, including freedom from cardio-
vascular disease and cancer, might today depend
on finding ways to ‘‘fine-tune’’ immunosuppres-
sive therapy, and for that purpose, donor-specific
antibodies might provide a more sensitive and
specific index than assays of peripheral T-cell
responses. Whether antibodies provide an index
that can direct and refine therapeutics is still
unknown, but the results of Suciu-Foca et al. (1)
and Gloor (11) suggest the answer may be ‘‘yes’’.
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This symposium begins with a paper by Ho
et al. (1) from the program headed by Nicole
Suciu-Foca at Columbia. This team has over the
years provided the most critical, incisive, and
independent insight into the involvement of
antibodies against donor HLA in the long-term
outcome of organ grafts (12). The original work
of this group was conducted when transplant
immunologists focused almost all attention on T
cells and the small measure of attention directed
at antibodies mainly concerned antibodies
against structures other than HLA. Now, this
group courageously takes a critical look at new
methods for detecting and measuring anti-HLA
antibodies. Two lessons especially to draw are
that (i) the technologies for analysis of antibodies
will continue to evolve and (ii) one must contin-
uously ask whether antibodies detected by one or
another new technique instruct us about whether
grafts will fail and/or why.
The second paper in this symposium originates
with Jim Gloor from the Mayo Clinic (11). Jim
may have more experience than anyone else in
the transplantation of organs into presensitized
recipients (including ABO-incompatible organs)
and in the diagnosis and management of anti-
body-mediated rejection. Jim uses this vast
experience not just as a platform for speculation
but also as a source of information for analysis of
what donor-specific antibodies mean and how to
treat patients with graft injury caused by those
antibodies. Jims approaches to diagnosis and
management are widely emulated by those who
care for children and adults with organ trans-
plants, and hence the clinician might do well to
carry this paper to rounds.
The third paper in this symposium was sub-
mitted by Marilia Cascalho and me (13). Marilia
is a B-cell biologist whose work provided key
insight into the mechanisms that diversify B cells
and maintain Ig levels in blood (14) and link
somatic hypermutation in B cells with DNA
repair (15). Marilia and I will offer a basic
perspective on what donor-specific antibodies
might be and what they might mean.
The fourth paper in this symposium is authored
by Lori West from Edmonton. Lori pioneered
ABO-incompatible transplantation of the heart in
infants and children (16). Her experience with
these transplants has taught important practical
lessons regarding organ allocation and manage-
ment [e.g., matching for ABO compatibility and
even just avoiding incompatibility does notmatter
for the young (17)]. Perhaps of greater importance
however is the lesson that fundamental advances
in immunology [e.g., spontaneous tolerance to
blood group antigens (18)] and presumably in
other fields can emerge from efforts to replace
failing organs in the young.
Addressing one aspect of transplantation
immunity, the usefulness of evaluating donor-
specific antibodies after transplantation, this
symposium necessarily neglects some related
subjects of equal or greater importance. This
symposium does not address the question of how
donor-specific antibodies are produced and how
production is regulated. Gloor (11) does consider
with authority therapeutic approaches to elimi-
nating those antibodies once they are made.
Understanding the cellular and molecular basis
for allogeneic responses of B cells may allow the
development of still more sophisticated and more
specific therapeutics, but this subject must await
a more focused consideration of B-cell biology.
Also put to the side is the question of how donor-
specific antibodies injure grafts. This subject has
been investigated rather thoroughly over the last
20 yr, mainly from the perspective of xenotrans-
plantation (19), but the impact of donor-specific
antibodies would seem better suited to a sympo-
sium on endothelial cell biology. However, the
reader should know that research into the impact
of antibodies on organ grafts almost always
eventuates the conclusion that depleting or stop-
ping the production of donor-specific antibodies
more effectively prevents graft injury than block-
ing the downstream effector pathways. Knowing
the properties of donor-specific antibodies as
discussed in the papers in this symposium can
only bring us closer to that goal.
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